The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism

J Am Med Dir Assoc. 2008 Nov;9(9):670-5. doi: 10.1016/j.jamda.2008.07.001. Epub 2008 Sep 25.

Abstract

Objective: To determine the effects of dopaminergic medication withdrawal in an elderly, demented and minimally ambulatory nursing home population with parkinsonism in New York City.

Methods: In our double-blind, randomized study, 11 patients (7 males, 4 females) were randomized into 2 groups: one group underwent levodopa medication withdrawal (experimental group) and the other group continued on their levodopa (control group). Patients were evaluated weekly over the course of a month with a neurologic examination and a series of assessment tools, including the motor UPDRS (Unified Parkinson's disease rating scale), Hoehn and Yahr staging scale, the Mini-Mental State Examination (MMSE) and the Nursing Assistant Behavioral Detection Form.

Setting: An academic nursing home in New York City.

Results: The patients had a mean age of 82.00 +/- 10.14 years, with a mean MMSE score of 9.50 +/- 6.60 out of 30.00 maximum. The control and experimental groups did not differ significantly with respect to age (P = .52), dementia severity (P = .35), nor severity of PD symptoms as measured by the UPDRS (P = .22) and Hoehn and Yahr staging (P = .65). Overall, no significant changes were observed between the control and experimental groups in cognitive, behavioral, and motor function across each time period. Of interest, 2 of the drug withdrawal patients showed modest improvements in cognitive function as measured by the MMSE.

Conclusion: Our findings suggest that in patients with advanced parkinsonism and dementia, dopaminergic medication withdrawal may be a feasible way to reduce polypharmacy and potential medication-related side effects, with a minimal risk of worsening motor deterioration. Therefore, our findings may have potential implications for a medication intervention that could prevent potential deleterious side effects and improve health-related quality of life in this frail population.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Dopamine Agents / administration & dosage
  • Dopamine Agents / therapeutic use*
  • Double-Blind Method
  • Female
  • Humans
  • Levodopa / administration & dosage
  • Levodopa / therapeutic use*
  • Male
  • New York City
  • Nursing Homes*
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Severity of Illness Index*
  • Substance Withdrawal Syndrome / physiopathology*

Substances

  • Dopamine Agents
  • Levodopa